NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S.
LAVAL, Quebec, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (NASDAQ: ACST) (TSXV: ACST) (the
“Company” or “Acasti”) is pleased to announce that, in connection with its overnight marketed
public offering previously announced on October 3, 2018, it has entered into an underwriting agreement with Mackie Research Capital
Corporation (the “Underwriter”) to sell 18,750,000 Class A Shares of the Company (“Common
Shares”) at a price of C$1.28 per Common Share (the “Offering Price”), for aggregate gross proceeds to
Acasti of C$24,000,000 (the “Offering”).
The Company has also granted the Underwriter an over-allotment option to purchase up to 2,812,500 Common Shares,
at the Offering Price, exercisable at any time up to 30 days after the closing date of the Offering, for additional aggregate gross
proceeds to Acasti of C$3,600,000.
Acasti’s TRILOGY Phase 3 clinical studies for its product candidate CaPre® (omega-3 phospholipid) are currently
underway and will be conducted at approximately 140 sites across North America. This Offering, along with the concurrent U.S.
Offering (as defined below), are intended to fund its TRILOGY Phase 3 program, to advance partnering discussions around the world
and for working capital and general corporate purposes.
On October 4, 2018, the Company also priced a separate and concurrent underwritten public offering of Common
Shares in the United States (the “U.S. Offering”) at a price of US$1.00 for total gross proceeds of
US$16,600,000.
The net proceeds received by the Company from the Offering, together with cash on hand and the U.S. Offering,
are intended to be used by the Company for the further development of CaPre and to complete the Company’s Phase 3 program through
to topline results, including completion of clinical site activation, patient enrollment and randomization, and production of
clinical materials (both CaPre and placebo) for the Company’s Phase 3 program; planning and initiation of the Company’s regulatory
(NDA) submission; expansion of business development activities; working capital; and other general corporate purposes.
The Offering is being made pursuant to a short-form prospectus filed in each of the provinces of Québec,
Ontario, Alberta, Manitoba and British Columbia, and otherwise by private placement exemption in those jurisdictions where the
Offering can lawfully be made, including the United States and Europe. The Common Shares will not be registered under the U.S.
Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States absent
registration or an exemption from the registration requirements including to Institutional Accredited Investors pursuant to
Regulation D of the United States Securities Act of 1993, as amended. This press release shall not constitute an offer to sell or
the solicitation of an offer to buy nor shall there be any sale of the Common Shares in any jurisdiction in which such offer,
solicitation or sale would be unlawful.
The Offering is scheduled to close on or about the week of October 22, 2018, and is subject to certain
conditions including, but not limited to, the receipt of all necessary regulatory approvals including the approval of the TSX
Venture Exchange (“TSXV”) and the NASDAQ Stock Market (“NASDAQ”).
About Acasti
Acasti Pharma is a biopharmaceutical innovator advancing a potentially best-in-class cardiovascular drug, CaPre®
(omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S.
population. Since its founding in 2008, Acasti Pharma has focused on addressing a critical market need for an effective, safe and
well-absorbing omega-3 therapeutic that can make a positive impact on the major blood lipids associated with cardiovascular disease
risk. The Company is developing CaPre in a Phase 3 clinical program in patients with severe hypertriglyceridemia, a market that
includes 3 to 4 million patients in the U.S. The addressable market may expand significantly if omega-3s demonstrate long-term
cardiovascular benefits in on-going outcomes studies (REDUCE-IT and STRENGTH). Acasti may need to conduct at least one additional
clinical trial to expand CaPre’s indications to this segment. Acasti’s strategy is to commercialize CaPre in the U.S. and the
Company is pursuing development and distribution partnerships to market CaPre in major countries around the world. For more
information, visit www.acastipharma.com.
Forward Looking Statements
Statements in this press release that are not statements of historical or current fact constitute
“forwardlooking information” within the meaning of Canadian securities laws and “forward-looking statements” within the meaning of
U.S. federal securities laws (collectively, “forward-looking statements”). Such forward-looking statements involve known and
unknown risks, uncertainties, and other unknown factors that could cause the actual results of Acasti to be materially different
from historical results or from any future results expressed or implied by such forward-looking statements. In addition to
statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms
“believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue” or other
similar expressions to be uncertain and forward looking. Readers are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release. Forward-looking statements in this press release include, but
are not limited to, information or statements about Acasti’s strategy, future operations, prospects and the plans of management;
Acasti’s ability to conduct all required clinical and non-clinical trials for CaPre, including the timing and results of those
trials; the timing and the outcome of licensing negotiations; CaPre’s potential to become the “best-in-class” cardiovascular drug
for treating severe Hypertriglyceridemia (HTG), and, Acasti’s ability to fund its continued operations.
The forward-looking statements contained in this press release are expressly qualified in their entirety by this
cautionary statement, the “Cautionary Note Regarding Forward-Looking Information” section contained in Acasti’s latest annual
report on Form 20-F and most recent management’s discussion and analysis (MD&A), which are available on SEDAR at www.sedar.com,
on EDGAR at www.sec.gov/edgar/shtml, and on the investor section of Acasti’s website at www.acastipharma.com. All forward-looking
statements in this press release are made as of the date of this press release. Acasti does not undertake to update any such
forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. The
forward-looking statements contained herein are also subject generally to assumptions and risks and uncertainties that are
described from time to time in Acasti’s public securities filings with the Securities and Exchange Commission and the Canadian
securities commissions, including Acasti’s latest annual report on Form 20-F and most recent MD&A.
Neither NASDAQ, the TSXV nor its Regulation Services Provider (as that term is defined in the
policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
